The Institute Spallanzani give you the opportunity to the team of researchers access to information and analysis of the blood of patients with infection Covid-19 in order to isolate, cultivate and characterize the pathogen.
"our goal is always the same: to do translational research, able to produce usable results in the short-term in activities of care," stresses the scientific director of the Istituto Spallanzani, Giuseppe Ippolito. "Human monoclonal antibodies are safe products, already widely used in cancer therapy and approved by all the regulatory agencies," explains Claudia Sala, senior scientist Vamres Lab, Fondazione Toscana Life Sciences. The experimental approach followed by the research group takes the name of Reverse Vaccinology 2.0, designed by Rino Rappuoli, chief scientist and head, external R&D of Gsk vaccines in Siena, as well as principal investigator of the project Vamres. It consists in recruiting patients convalescent or recovered from coronavirus and remove the blood that is used to isolate B cells, producers of monoclonal antibodies. These are cloned and expressed in appropriate cellular systems, to be then tested in in vitro assays.
Even in this time of emergency, the Republic is at the service of its readers.
To understand the changing world with news check, surveys, data updated, without never hiding anything to the citizens